Clinical trials for Pulmonary hypertension

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Pulmonary hypertension. For all clinical trials, go to clinical trials search

This list shows clinical trials for Pulmonary hypertension

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Pulmonary hypertension
Title Recruitment status Location
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP). Recruiting United Kingdom
EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension Recruiting United Kingdom
Not Recruiting United Kingdom
Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). - CHEST-2 Not Recruiting United Kingdom
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension Not Recruiting United Kingdom
ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH Not Recruiting United Kingdom
Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). - CHEST-1 Study Not Recruiting United Kingdom
Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of bosentan in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) - BENEFIT Not Recruiting United Kingdom
A research project to find out whether adding bosentan to inhaled nitric oxide in newborns with persistent pulmonary hypertension of newborns (PPHN) is a supporting and safe therapy. Not Recruiting United Kingdom
A multi-center, multinational, randomized, double-blind, placebo-controlled, proof of concept trial to assess the effects of a subject-optimized dose of UK-369,003 Modified Release on exercise capacity in subjects with pulmonary hypertension associated with chronic obstructive pulmonary disease. Not Recruiting United Kingdom

Page last reviewed:

Next review due: